Clinicopathological study of gall bladder carcinoma at a tertiary care hospital

Objective: To determine the frequency of carcinoma of Gall Bladder in Hospitalized patients undergoing surgeries for cholelithiasis at tertiary care Hospital. Study Setting: General surgery department of Muhammad Medical College Mirpurkhas. Study Design: Descriptive. Study Duration: From 2018 to 2019. Methodology: All the patients of cholelithiasis diagnosed via trans-abdominal ultrasound, those who underwent cholecystectomies and either of gender were included. After surgeries, specimens immediately were sent to the Hospital diagnostic laboratory to evaluate the gall bladder carcinoma. The information obtained was noted on a pre-designed proforma. Results: A total 200 patient of gall bladder stone disease were observed who underwent cholecystectomies. Average age was 53.8+5.62 years and male to female ratio was 1:2.5. Incidence of carcinoma of gall bladder was 4%, which was significantly associated to gall bladder mass, chronic calculus cholecystitis and porcelain gall bladder (p=0.001). Conclusion: The incidence of the gall bladder cancer in the study population was 4% and its relationship with gall bladder diseases (chronic cholecystitis and porcelain) was found to be significant.

Download Full-text

Role of EGFR and HER-2/NEU Expression in Gall Bladder Carcinoma

Journal of Laboratory Physicians ◽

10.1055/s-0041-1726561 ◽

2021 ◽

Author(s):

Chhanda Das ◽

Madhumita Mukhopadhyay ◽

Srijana Subba ◽

Ashis Kumar Saha ◽

Biswanath Mukhopadhyay

Keyword(s):

Gall Bladder ◽

Bladder Carcinoma ◽

Tertiary Care ◽

Molecular Therapy ◽

Tumor Type ◽

Care Hospital ◽

Gall Bladder Carcinoma ◽

Poorly Differentiated ◽

Her 2 ◽

Well Differentiated

Abstract Background Gall bladder carcinoma (GBC) is the most common malignancy of the biliary tract. Being known for its geographical and racial variations, and compared with the global statistics, its incidence is higher in the Indian subcontinent, mainly in the northern and eastern regions, accounting for 80 to 95% of cases. Aims and Objectives This study was conducted to evaluate the clinic-pathological spectrum and expression of EGFR and HER-2/NEU in GBCs and to understand their relation to prognosis, paving the way for targeted therapies for better treatment outcomes and patient survival. Materials and Methods This is a prospective study performed in a tertiary care hospital in 30 resected specimens of GBC cases recorded in our Department of Pathology from November 2017 to November 2019. Clinical history including the radiological reports and demographic parameters were included in the study pro forma. Immunohistochemical (IHC) staining for EGFR and HER-2/NEU was performed on all the selected cases. Clinicopathologic parameters like age, sex, histologic type, perineural, and lymphovascular invasion were compared and correlated with EGFR and HER-2/NEU status. Results Expression of EGFR was found in 93.33% of cases, which showed a highly significant correlation with histological tumor type (p = 0.000). HER-2/NEU expression was found in 56.66% of cases, which also showed a significant correlation with histological tumour type (p = 0.021). We found most of the cases with strong EGFR immunoreactivity (3+) were poorly differentiated tumors and most of the cases showing weak immunoreactivity for EGFR (1+) were well-differentiated. Conversely, in case of HER-2/NEU immunoreactivity, strong staining (3+) was seen in well-differentiated tumors and weak staining (1+) in poorly differentiated tumors. A significant correlation was also found between EGFR and HER-2/NEU expression (p = 0.000) and between cholelithiasis and EGFR expression (p = 0.033). Conclusion EGFR is expressed in most cases of GBC. Its expression is more in poorly differentiated carcinomas as compared to the well-differentiated carcinomas, whereas HER-2/NEU expression is more in well-differentiated carcinomas. Therefore, they may serve as independent prognostic factors and also as targets for molecular therapy in GBCs.

Download Full-text